Resight Therapeutics completes angel round to advance iPSC-derived ophthalmic therapies

Recently, Resight Therapeutics announced the completion of an Angel funding round raising tens of millions of RMB. This round was led by Huafang Capital, with participation from Hangzhou STI Group.

The raised funds will be allocated to advancing the company's leading pipeline of iPSC-differentiated corneal endothelial cell therapies and to the development of its early-stage research pipelines driven by proprietary technologies.

Resight Therapeutics, founded in September 2024, focuses on developing cell-based therapies and addressing critical unmet clinical needs in ocular diseases. The company's team brings over a decade of experience in both basic and clinical research for ophthalmic cell therapies, as well as stem cell industry expertise, with their research findings consistently published in leading international journals.

Leveraging its proprietary iPSC differentiation technology platform and an AI-powered small molecule reprogramming platform, Resight Therapeutics is dedicated to creating breakthrough cell therapies for urgent clinical needs in corneal and retinal diseases. The company has established collaborations with several top-tier ophthalmic research institutions and hospitals to accelerate the clinical translation of innovative treatments and provide patients with safer, more effective therapeutic options.